The research, conducted by Dr. Sebastian Johnston of London’s VirTus Respiratory Research, examines the efficacy of the oral capsid inhibitor within a double-blind, placebo-controlled study. By targeting rhinovirus, which triggers roughly half of all acute COPD exacerbations, the treatment aims to mitigate the lung function decline and mortality risks associated with viral respiratory infections. Altesa BioSciences frames the data as a potential shift in how clinicians address the underlying causes of disease rather than merely managing symptoms. This announcement follows the company's recent launch of the Phase 2b CARDINAL clinical trial, which focuses on evaluating whether vapendavir can improve airway symptoms and reduce the duration of illness. While findings remain under embargo until the Barcelona session, the selection for an oral presentation at the ERS congress signals growing industry attention toward the drug's role in the respiratory care landscape.
Altesa BioSciences to Present New Vapendavir Data in Barcelona
Dr. Sebastian Johnston will present clinical findings demonstrating that the investigational drug vapendavir reduces inflammatory biomarkers in COPD patients during the European Respiratory Society International Congress. The oral presentation, scheduled for September 9, 2026, highlights progress in treating rhinovirus-associated complications for those with chronic lung disease.
Comments (0)
No comments yet. Be the first!